Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact
IPF And Systemic Sclerosis Trials Abandoned
Executive Summary
The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.
You may also be interested in...
End Of An Era As Galapagos CEO Van De Stolpe Retires
Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.
Toledo Data Fail To Give Galapagos A Lift
Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.
Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."